化疗联合胸腺肽α1治疗乳腺癌的基础与临床观察

目的评价观察化疗联合胸腺肽α1对乳腺癌患者毒副作用及免疫功能的影响。方法87例乳腺癌患者随机分为治疗组43例和对照组44例。对照组单用化疗。治疗组采用胸腺肽α1＋化疗，胸腺肽α1给药方案：化疗当天开始1．6mg／周，皮下注射，直至患者完成2个疗程的化疗。结果2组均按期完成化疗计划。化疗期间，治疗组19例，对照组有31例WBC〈4×10^9／L。2组WBC〈4×10^9／L患者的例数差异有统计学意义（x^2=6．14，P〈0．05）。对照组有26例患者，治疗组有34例出现胃肠道不良反应。2组胃肠道不良反应发生率差异有统计学意义（x^2=4．06，P〈0．05）。治疗组化疗后细胞免疫指标水平高于对照组，差异有统计学意义（P〈0．05或P〈0．01）。结论胸腺肽α1配合化疗能提高患者的免疫功能，改善患者生活质量。

Combination of thymosin alpha 1 and chemotherapy for treating breast cancer

Objective To evaluate the impact of the thymosin alpha 1 on the toxicity and cellular immune function during chemotherapeutic treatment of breast cancer. Methods Eighty-seven patients of breast cancer were randomly divided into two groups: study group (chemotherapy of CAF combined with thymosin alpha 1) and control group(chemotherapy of CAF alone). The patients were given thyrnosin alpha 1 at the dose of 1.6 mg per week and at the end of 2 periods of chemotherapy. Results Rates of gastrointestinal upset and bone marrow depression in study group were significantly lower than those in control group(P<0.05). The levels of CD3, CD4, CD4/CD8, IL-2 and IL-12 of patients in study group were significantly higher than those of control group after chemotherapy (P<0.05). Conclusion The combination of thymosin alpha 1 and chemotherapy for the treatment of breast cancer can enhance cellular immune function and improve the quality of breast cancer patient's life.